PRODUCT DESCRIPTION:

NATtrol MERS-S. cerevisiae Recombinant (NATCOV(MR)-BIO) is with purified, intact yeast cells that have been chemically modified to render them non-infectious and refrigerator stable. Each vial contains 0.6 mL of NATtrol Middle East Respiratory Syndrome-Coronavirus recombinant sequence in S. cerevisiae; the MERS specific sequence is less than 500 bp and represents a small, non-infectious portion of the virus. NATCOV(MR)-BIO is supplied in a purified protein matrix that mimics the composition of a true clinical specimen.

INTENDED USE:

NATtrol MERS-S. cerevisiae is Recombinant designed to evaluate the performance of nucleic acid tests for determination of the presence of MERS-Coronavirus RNA. NATCOV(MR)-BIO can also be used for validation of clinical assays, development of diagnostic tests and training of laboratory personnel. NATCOV(MR)-BIO contains intact yeast cells and should be run in a manner identical to that used for clinical specimens.

ETIOLOGIC STATUS/BIOHAZARD TESTING:

NATtrol inactivation was carried out on the MERS-S. cerevisiae Recombinant stock used to formulate this product. The inactivation was verified by the absence of growth in validated tissue culture based infectivity assays and growth
protocols. Purified protein matrix used in the manufacture of this product is treated with 0.09% sodium azide.
It was manufactured from materials that have been tested and found non-reactive at the donor level for HIV-1/HIV-2 Antibody, HBsAg and HCV Antibody by FDA licensed donor screening test methods. All materials are also tested for HIV-1  and HCV by FDA approved Nucleic Acid Test (NAT) methods. Heat inactivated bovine based source materials used in the manufacture of this product meet applicable USDA requirements for abattoir sourced animals, traceability and country of origin. The materials were collected at USDA licensed establishments or legally imported from countries recognized by the USDA as negligible or controlled for risk for Bovine Spongiform Encephalopathy (BSE) and other exotic disease agents. Donor animals were inspected ante and post mortem at the abattoir as required by the USDA.

 

NATtrol MERS Recombinant Pack   NATMR-BIO
Product Description:

NATtrol MERS Recombinant Pack (NATMR-BIO)* is formulated with pure, intact yeast cells that have been chemically modified to be non-infectious and refrigerator stable. 1 x 0.2mL vial of NATtrol™ Middle East Respiratory Syndrome-Coronavirus Recombinant Sequence 1 in S. cerevisiae in NATMR-BIO, 1 x 0.2mL Vial of NATtrol™ Middle East Respiratory Syndrome-Coronavirus Recombinant Sequence 2 in S. cerevisiae, and 1 x 0.5mL vial of negative control; MERS specific sequences are shorter than 500 bp and represent short, non-infectious parts of the virus. NATMR-BIO is supplied in a purified protein matrix that mimics the structure of a true clinical sample.

NATtrol MERS-CoV Stock (Qualitative) (1 mL)

NATMERS-ST Zeptometrix 1 mL 612 EUR

Recombinant S. cerevisiae TIM14

CR26-10ug Novoprotein 10ug 242.4 EUR

Recombinant S. cerevisiae TIM14

CR26-1mg Novoprotein 1mg 2983.2 EUR

Recombinant S. cerevisiae TIM14

CR26-500ug Novoprotein 500ug 1935.6 EUR

Recombinant S. cerevisiae TIM14

CR26-50ug Novoprotein 50ug 595.2 EUR

ATP Sulfurylase, S. cerevisiae Recombinant

P1542-100 Biovision 100 µg 1548 EUR

ATP Sulfurylase, S. cerevisiae Recombinant

P1542-20 Biovision 20 µg 429.6 EUR

Recombinant Human COX17 (S. cerevisiae)

COX17-448H Creative BioMart 200ug 398.4 EUR

Recombinant S. Cerevisiae TIM16 Protein

MBS2557614-001mg MyBiosource 0.01mg 220 EUR

Recombinant S. Cerevisiae TIM16 Protein

MBS2557614-005mg MyBiosource 0.05mg 505 EUR

Recombinant S. Cerevisiae TIM16 Protein

MBS2557614-5x005mg MyBiosource 5x0.05mg 2270 EUR

Recombinant S. Cerevisiae TIM14 Protein

MBS2557615-001mg MyBiosource 0.01mg 220 EUR

Recombinant S. Cerevisiae TIM14 Protein

MBS2557615-005mg MyBiosource 0.05mg 505 EUR

Recombinant S. Cerevisiae TIM14 Protein

MBS2557615-5x005mg MyBiosource 5x0.05mg 2270 EUR

Intended use:

The NATtrol MERS Recombinant Pack is designed to evaluate the performance of nucleic acid tests for the determination of the presence of MERS-Coronavirus RNA. NATMR-BIO can also be used for validation of clinical assays, development of diagnostic tests and training of laboratory personnel.

NATMR-BIO contains intact yeast cells and should be run in a manner identical to that used for clinical specimens.

Leave a Reply

Your email address will not be published. Required fields are marked *